Publicaciones en las que colabora con Eduardo Ansorena Artieda (16)

2023

  1. Antifibrogenic and apoptotic effects of Ocoxin in cultured rat hepatic stellate cells

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 881-890

  2. Endothelial NOX5 overexpression induces changes in the cardiac gene profile: potential impact in myocardial infarction?

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 787-797

2021

  1. Optimization of a GDNF production method based on Semliki Forest virus vector

    European Journal of Pharmaceutical Sciences, Vol. 159

2020

  1. Induction of Cyclooxygenase-2 by Overexpression of the Human NADPH Oxidase 5 (NOX5) Gene in Aortic Endothelial Cells

    Cells, Vol. 9, Núm. 3

2019

  1. Role of AGAP2 in the profibrogenic effects induced by TGFβ in LX-2 hepatic stellate cells

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1866, Núm. 4, pp. 673-685

2016

  1. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

2013

  1. A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system

    International Journal of Pharmaceutics, Vol. 440, Núm. 1, pp. 19-26

2011

  1. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease

    Movement Disorders, Vol. 26, Núm. 10, pp. 1943-1947

2010

  1. Production of highly pure human glycosylated GDNF in a mammalian cell line

    International Journal of Pharmaceutics, Vol. 385, Núm. 1-2, pp. 6-11

2009

  1. Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease

    Journal of Controlled Release, Vol. 135, Núm. 2, pp. 119-126

2008

  1. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, Núm. 3, pp. 844-851

2007

  1. Microencapsulación de factores neurotróficos: Aplicación al tratamiento de la enfermedad de Parkinson

    Mapfre Medicina, Vol. 18, Núm. 4, pp. 240-248

  2. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor

    International Journal of Pharmaceutics, Vol. 344, Núm. 1-2, pp. 9-15

2006

  1. Differential regulation of the JNK/AP-1 pathway by S-adenosylmethionine and methylthioadenosine in primary rat hepatocytes versus HuH7 hepatoma cells

    American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 290, Núm. 6

  2. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 3, pp. 325-335

2002

  1. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells

    Hepatology, Vol. 35, Núm. 2, pp. 274-280